DE2610886C2 - - Google Patents

Info

Publication number
DE2610886C2
DE2610886C2 DE2610886A DE2610886A DE2610886C2 DE 2610886 C2 DE2610886 C2 DE 2610886C2 DE 2610886 A DE2610886 A DE 2610886A DE 2610886 A DE2610886 A DE 2610886A DE 2610886 C2 DE2610886 C2 DE 2610886C2
Authority
DE
Germany
Prior art keywords
compound
general formula
group
preparation
compounds according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2610886A
Other languages
German (de)
English (en)
Other versions
DE2610886A1 (de
Inventor
Hendricus Bernardus Antonius Utrecht Nl Welle
Volkert Weesp Nl Claassen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duphar International Research BV
Original Assignee
Duphar International Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research BV filed Critical Duphar International Research BV
Publication of DE2610886A1 publication Critical patent/DE2610886A1/de
Application granted granted Critical
Publication of DE2610886C2 publication Critical patent/DE2610886C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19762610886 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung Granted DE2610886A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (2)

Publication Number Publication Date
DE2610886A1 DE2610886A1 (de) 1976-10-07
DE2610886C2 true DE2610886C2 (cg-RX-API-DMAC10.html) 1987-09-24

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762610886 Granted DE2610886A1 (de) 1975-03-20 1976-03-16 Verbindungen mit antidepressiver wirkung

Country Status (27)

Country Link
US (1) US4085225A (cg-RX-API-DMAC10.html)
JP (1) JPS6026776B2 (cg-RX-API-DMAC10.html)
AR (2) AR211011A1 (cg-RX-API-DMAC10.html)
AT (1) AT340895B (cg-RX-API-DMAC10.html)
AU (1) AU505358B2 (cg-RX-API-DMAC10.html)
BE (1) BE839744A (cg-RX-API-DMAC10.html)
CA (1) CA1076142A (cg-RX-API-DMAC10.html)
CH (4) CH626057A5 (cg-RX-API-DMAC10.html)
DD (1) DD128332A5 (cg-RX-API-DMAC10.html)
DE (1) DE2610886A1 (cg-RX-API-DMAC10.html)
DK (1) DK144942C (cg-RX-API-DMAC10.html)
ES (1) ES446192A1 (cg-RX-API-DMAC10.html)
FI (1) FI61875C (cg-RX-API-DMAC10.html)
FR (1) FR2304336A1 (cg-RX-API-DMAC10.html)
GB (1) GB1535226A (cg-RX-API-DMAC10.html)
GR (1) GR60052B (cg-RX-API-DMAC10.html)
HU (1) HU171030B (cg-RX-API-DMAC10.html)
IE (1) IE43768B1 (cg-RX-API-DMAC10.html)
IL (1) IL49238A (cg-RX-API-DMAC10.html)
IT (1) IT1063064B (cg-RX-API-DMAC10.html)
MX (1) MX9203723A (cg-RX-API-DMAC10.html)
NL (1) NL7503310A (cg-RX-API-DMAC10.html)
PL (3) PL100052B1 (cg-RX-API-DMAC10.html)
SE (1) SE410312B (cg-RX-API-DMAC10.html)
SU (3) SU635867A3 (cg-RX-API-DMAC10.html)
YU (1) YU39345B (cg-RX-API-DMAC10.html)
ZA (1) ZA761434B (cg-RX-API-DMAC10.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (en) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
IN182588B (cg-RX-API-DMAC10.html) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (cg-RX-API-DMAC10.html) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
EP1276478A2 (en) * 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
NZ532033A (en) * 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
ATE449633T1 (de) 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
DE602004028150D1 (de) * 2003-11-26 2010-08-26 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
AU2006239920A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
SG163588A1 (en) 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2491038T (pt) 2009-10-23 2016-07-14 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disubstituídos como modeladores de recetores de orexina
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
WO2014178064A2 (en) * 2013-04-03 2014-11-06 Zcl Chemicals Limited "an improved process for the preparation of fluvoxamine maleate"
PL3104847T3 (pl) 2014-02-07 2021-07-05 Támogatott Kutatócsoportok Irodája Nowe zastosowanie związków agonistycznych receptora sigma-1
MX2021005502A (es) 2014-03-28 2023-01-16 Azevan Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades neurodegenerativas.
KR102559922B1 (ko) 2016-03-10 2023-07-25 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
MA46898A (fr) 2016-11-24 2019-10-02 Sigmadrugs Kutato Korlatolt Feleloessegue Tarsasag Compositions pour la conservation d'organes
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral
KR20220049526A (ko) 2019-07-19 2022-04-21 바이오엑셀 테라퓨틱스 인코포레이티드 비-진정성 덱스메데토미딘 치료 양생법
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
BE839744A (fr) 1976-09-20
AU1214776A (en) 1977-09-22
CH629761A5 (de) 1982-05-14
AR211011A1 (es) 1977-10-14
CH629477A5 (de) 1982-04-30
SU620206A3 (ru) 1978-08-15
DK144942B (da) 1982-07-12
IT1063064B (it) 1985-02-11
HU171030B (hu) 1977-10-28
FR2304336B1 (cg-RX-API-DMAC10.html) 1979-09-28
ZA761434B (en) 1977-10-26
DD128332A5 (de) 1977-11-09
CH629184A5 (de) 1982-04-15
DE2610886A1 (de) 1976-10-07
SU635867A3 (ru) 1978-11-30
AU505358B2 (en) 1979-11-15
IL49238A (en) 1978-08-31
PL100052B1 (pl) 1978-08-31
GR60052B (en) 1978-04-04
GB1535226A (en) 1978-12-13
IE43768L (en) 1976-09-20
SE7603341L (sv) 1976-09-21
PL100614B1 (pl) 1978-10-31
CA1076142A (en) 1980-04-22
FI61875C (fi) 1982-10-11
JPS51125345A (en) 1976-11-01
FI760699A7 (cg-RX-API-DMAC10.html) 1976-09-21
DK144942C (da) 1982-12-06
ATA195476A (de) 1977-05-15
NL7503310A (nl) 1976-09-22
IE43768B1 (en) 1981-05-20
ES446192A1 (es) 1977-10-01
YU39345B (en) 1984-10-31
IL49238A0 (en) 1976-05-31
SU645559A3 (ru) 1979-01-30
AT340895B (de) 1978-01-10
JPS6026776B2 (ja) 1985-06-25
US4085225A (en) 1978-04-18
MX9203723A (es) 1992-07-01
FR2304336A1 (fr) 1976-10-15
CH626057A5 (cg-RX-API-DMAC10.html) 1981-10-30
SE410312B (sv) 1979-10-08
PL101951B1 (pl) 1979-02-28
DK115976A (da) 1976-09-21
FI61875B (fi) 1982-06-30
AR211153A1 (es) 1977-10-31
YU71476A (en) 1982-10-31

Similar Documents

Publication Publication Date Title
DE2610886C2 (cg-RX-API-DMAC10.html)
DE2434911C2 (de) Phenyläthylamin-Derivate und pharmazeutische Zusammensetzungen
DD141520A5 (de) Verfahren zur herstellung neuer derivate von 4-amino-5-alkylsulfonyl-ortho-anisamiden
DE2634288B2 (cg-RX-API-DMAC10.html)
DE3329628C2 (cg-RX-API-DMAC10.html)
DE3002367A1 (de) 2-substituierte trans-5-aryl-2,3,4,4a,5, 9b-hexahydro-1h-pyrido eckige klammer auf 4,3-b eckige klammer zu indole
DE2305092C2 (cg-RX-API-DMAC10.html)
DE2044172C3 (de) Pyrrolderivate, ein Verfahren zu ihrer Herstellung und Arzneimittel
EP0002672B1 (de) Substituierte Pyrrolidine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE3320394A1 (de) Optisch aktive n-arylierte oxazolidinon-(2)-derivate, deren verwendung als spezifische und reversible inhibitoren von monoaminooxydase des b-typs sowie verfahren zu deren herstellung
EP0096279B1 (de) N-(2-Methoxyethyl)-noroxymorphon, dessen Säureadditionssalze, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2609437C2 (cg-RX-API-DMAC10.html)
DE2611118C2 (cg-RX-API-DMAC10.html)
DE2609862C2 (cg-RX-API-DMAC10.html)
DE2610679C2 (de) Sulfinylgruppenhaltige Oximätherderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
DE2610302A1 (de) Antidepressive verbindungen
DE2615129A1 (de) Tripeptide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
DE2421549A1 (de) Naphthalinderivate, verfahren zu ihrer herstellung und arzneimittel
DE2034588B2 (de) ej-Dimethoxy^-benzylisochinoline, Verfahren zu ihrer Herstellung und Arzneimittel
AT282593B (de) Verfahren zur herstellung von neuem racemischem oder optisch aktivem (1-2'-nitrilophenoxy)-2-hydroxy-3-isopropylaminopropan und dessen salzen
EP0413302A1 (de) Neue 1,3-Oxazine
DE1518334A1 (de) Neu substituierte Benzylamine und ihre Salze sowie Verfahren zu ihrer Herstellung
DE1951614B2 (de) Substituierte Benzylalkohol, deren physiologisch verträgliche Salze, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2402989B2 (de) Neue Benzylamine, sie enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DD298100A5 (de) Aminoalkylfuranderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR. MEYER-ROXLAU, R., DIP

8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN

D2 Grant after examination
8364 No opposition during term of opposition